BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 32591970)

  • 1. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
    Coskun Benlidayi I; Kurtaran B; Tirasci E; Guzel R
    Rheumatol Int; 2020 Oct; 40(10):1707-1716. PubMed ID: 32591970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
    Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
    RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
    Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
    J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
    Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM;
    Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857
    [No Abstract]   [Full Text] [Related]  

  • 5. [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
    Malek SA; Bouchti IE
    Pan Afr Med J; 2020; 35(Suppl 2):134. PubMed ID: 33193949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.
    Perricone C; Triggianese P; Bartoloni E; Cafaro G; Bonifacio AF; Bursi R; Perricone R; Gerli R
    J Autoimmun; 2020 Jul; 111():102468. PubMed ID: 32317220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19: an unexpected indication for anti-rheumatic therapies?
    Lucchino B; Di Franco M; Conti F
    Rheumatology (Oxford); 2020 Jun; 59(6):1200-1203. PubMed ID: 32374874
    [No Abstract]   [Full Text] [Related]  

  • 8. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept.
    Duret PM; Sebbag E; Mallick A; Gravier S; Spielmann L; Messer L
    Ann Rheum Dis; 2020 Sep; 79(9):1251-1252. PubMed ID: 32354772
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
    He F; Luo Q; Lei M; Fan L; Shao X; Hu K; Qin S; Yu N; Cao J; Yang L
    Clin Rheumatol; 2020 Sep; 39(9):2803-2810. PubMed ID: 32725351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to manage rheumatic patients during the coronavirus pandemic.
    Parisi S; Ditto MC; Finucci A; Fusaro E
    Panminerva Med; 2020 Sep; 62(3):176-177. PubMed ID: 32343511
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.
    Türk SM; Öztürk Z; Karataş D; Erkorkmaz Ü; Gönüllü E
    Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.
    Colafrancesco S; Scrivo R; Barbati C; Conti F; Priori R
    Front Immunol; 2020; 11():1439. PubMed ID: 32655577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
    Montero F; Martínez-Barrio J; Serrano-Benavente B; González T; Rivera J; Molina Collada J; Castrejón I; Álvaro-Gracia J
    Rheumatol Int; 2020 Oct; 40(10):1593-1598. PubMed ID: 32794113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.
    d'Ettorre G; Recchia G; Ridolfi M; Siccardi G; Pinacchio C; Innocenti GP; Santinelli L; Frasca F; Bitossi C; Ceccarelli G; Borrazzo C; Antonelli G; Scagnolari C; Mastroianni CM
    Medicine (Baltimore); 2020 Sep; 99(36):e21803. PubMed ID: 32899009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.
    Licciardi F; Giani T; Baldini L; Favalli EG; Caporali R; Cimaz R
    Pediatr Rheumatol Online J; 2020 Apr; 18(1):35. PubMed ID: 32321540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab.
    De Luna G; Habibi A; Deux JF; Colard M; Pham Hung d'Alexandry d'Orengiani AL; Schlemmer F; Joher N; Kassasseya C; Pawlotsky JM; Ourghanlian C; Michel M; Mekontso-Dessap A; Bartolucci P
    Am J Hematol; 2020 Jul; 95(7):876-878. PubMed ID: 32282956
    [No Abstract]   [Full Text] [Related]  

  • 17. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
    Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N
    Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
    Pablos JL; Galindo M; Carmona L; Lledó A; Retuerto M; Blanco R; Gonzalez-Gay MA; Martinez-Lopez D; Castrejón I; Alvaro-Gracia JM; Fernández Fernández D; Mera-Varela A; Manrique-Arija S; Mena Vázquez N; Fernandez-Nebro A; ;
    Ann Rheum Dis; 2020 Dec; 79(12):1544-1549. PubMed ID: 32796045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
    Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.